尋常性天疱瘡薬市場展望 2034: 承認、臨床状況、疫学、NDA 状況、収益、作用機序、主要な治療法、主要企業 - DelveInsight レポート
2025年 04月 15日
Key players in the Pemphigus Vulgaris field: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Inc., Kemia, Inc., argenx, Rho Federation Systems Division, Inc. and others.
Pemphigus Vulgaris Market Overview (Albany, USA) – DelveInsight’s report, “Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast – 2034,” provides a detailed assessment of Pemphigus Vulgaris, covering historical and projected epidemiological trends, treatment practices, and market dynamics in the US, EU4 (Germany, France, Italy, Spain), UK, and Japan.
This comprehensive analysis focuses on trends in current treatment approaches, emerging treatment options, market shares of individual drugs, and expected market size from 2020 to 2034. The study further evaluates the market drivers, challenges, unmet clinical needs, and potential opportunities in the pemphigus vulgaris sector.
👉To gain more insights into Pemphigus Vulgaris market trends, treatment pathways, and drug adoption, click here: Pemphigus Vulgaris Market Forecast
Key Takeaways from the Pemphigus Vulgaris Market Report:
The pemphigus vulgaris market is projected to register robust growth at a remarkable CAGR throughout the forecast period (2020-2034).
The US market alone was worth approximately $2,000.250 million by 2023.
January 2025: Cabaletta Bio shared positive updates from a Phase 1/2 study evaluating an autologous CART therapy (DSG3-CAART and CABA-201) in patients with active pemphigus vulgaris.
September 2024: IRIS R&D disclosed results from a study evaluating the combination of rituximab and AB-101 in autoimmune diseases, including pemphigus vulgaris.
August 2024: The first patients are treated in a basket IIT trial with AlloNK® plus rituximab for autoimmune diseases including PV, RA, GPA/MPA and SLE, highlighting the community's access to innovative therapies.
Epidemiological highlights:
In 2023, the United States is projected to reach nearly 40,000 PV , rising by 2034.
In 2022, 14,000 diagnosed cases were noted in the United States, with the highest prevalence in the 60-69 age group , with the least number of cases in the 0-17 age group.
Breakdown of severity (US, 2022): 6,000 mild , 4,000 moderate , 4,300 severe cases.
Among EU4+UK, Germany had the highest prevalence of diagnosed cases with 8,000 , followed by the UK. France reported the lowest rate at around 3,000.
Over the 7MM, women had a higher diagnosed prevalence compared with men throughout the study period (2020-2034).
With an increasing number of innovative medicines in development and growing awareness, the pemphigus vulgaris market is poised to significantly evolve and expand.
Pemphigus vulgaris – disease overview
Pemphigus vulgaris (PV) is a rare, life-threatening autoimmune disease that causes blisters on the skin and mucous membranes. It occurs when the immune system produces autoantibodies against desmoglein, a key adhesive protein in the skin, causing cell detachment and the formation of blisters.
PV most commonly occurs in middle-aged and elderly people and often begins with painful oral lesions before progressing to the skin. Diagnosis of PV includes clinical evaluation, biopsy, immunofluorescence, and detection of autoantibodies. Treatment primarily includes corticosteroids and immunosuppressants such as rituximab, azathioprine, and mycophenolate mofetil.
The advent of biologics and targeted therapies has reshaped the treatment paradigm, reducing long-term side effects and improving outcomes, but long-term monitoring remains essential to manage recurrence and treatment-related risks.
👉Get a free sample of Pemphigus Vulgaris Market Forecast and Size Report: https://www.delveinsight.com/report-store/pemphigus-vulgaris-market
Market Drivers and Challenges
Main propulsion:
Increased awareness of the disease and improved diagnosis
Increasing prevalence of autoimmune diseases
Advances in biologics (e.g., rituximab, CAART, AlloNK®)
Ongoing research and development and positive regulatory momentum
barrier:
High cost of biological treatment
Diagnostic challenges due to disease rarity
Access restrictions in certain areas
Side effects of long-term immunosuppressive therapy
Small patient pool hinders large-scale clinical trials
Despite these hurdles, the overall market is expected to benefit from increased investment in innovation and expanding access to healthcare.
Epidemiology of Pemphigus Vulgaris (2020–2034)
The report provides a detailed epidemiological snapshot of the entire 7MM, including:
Overall PV penetration rate
Prevalence by severity
Prevalence by gender
Temporary and chronic diagnoses
📊 For detailed forecasts, download the full epidemiology report: Pemphigus Vulgaris Epidemiology Forecast
Pipeline Insights and Drug Uptake
The adoption analysis tracks the adoption of both recent and upcoming therapies to measure market penetration, patient share, and sales trends.
Pipeline Therapies and Developers:
PRN1008 – Principia Biopharma
Mycophenolate Mofetil – Genentech, Inc.
KC706 – Kemia Corporation
Efgartigimod PH20 SC – Argencus
mRNA-1273 (Moderna) – Rho Federal Systems Division, Inc.
Recent strategic moves, licensing agreements, clinical milestones, and corporate collaborations are also analyzed.
👉 Discover key pipeline therapies likely to dominate future market share. Pemphigus Vulgaris Treatment Landscape
Scope and scope of the report
Forecast period: 2020-2034
Applicable regions: US, EU5 (Germany, France, Italy, Spain, UK), Japan
Major companies: Roche, Cabaletta Bio, Principia Biopharma, Genentech, Kemia, argenx, Rho Federal Systems Division
Main treatments: PRN1008, mycophenolate mofetil, KC706, efgartigimod PH20 SC, Moderna mRNA-1273
Analysis tools: SWOT, PESTLE, BCG matrix, Porter's five forces
Additional focus: unmet need, KOL insights, market access, and reimbursement landscape
📖For company level analysis, clinical pipeline review, and market access insights, please visit: Pemphigus Vulgaris Clinical Trials and Market Assessment
Table of Contents Overview
introduction
executive summary
SWOT Analysis
Patient Share Overview
Market Snapshot
Background of the disease
Epidemiology insights
Country-level epidemiology
Current treatment status
Unmet needs
New Treatments
Market Forecast
Market analysis by country
Market Access and Reimbursement
Market Drivers
Market Barriers
appendix
Research Methods
About DelveInsight
Disclaimer
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm focused on life sciences, providing end-to-end support to pharmaceutical companies, providing strategic insights to improve performance and competitive advantage.
